The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of palbociclib combined with retifanlimab in patients with advanced dedifferentiated liposarcoma.
 
Sandra P. D'Angelo
Honoraria - Adaptimmune; GlaxoSmithKline; Pfizer; Rain Therapeutics; SERVIER
Consulting or Advisory Role - Adaptimmune; GlaxoSmithKline; Nektar; Pfizer; Rain Therapeutics; Rain Therapeutics; Servier
 
Evan Rosenbaum
No Relationships to Disclose
 
Rodrigo Gularte Mérida
No Relationships to Disclose
 
Mark Andrew Dickson
Research Funding - AADi (Inst); Lilly (Inst); Sumitomo Dainippon Pharma Oncology (Inst)
 
Mary Louise Keohan
No Relationships to Disclose
 
Mrinal M. Gounder
Honoraria - Flatiron Health; Guidepoint Global; Med Learning Group; Medscape; More Health; PER; PER; touchIME
Consulting or Advisory Role - Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; Daiichi Sankyo; Epizyme; Karyopharm Therapeutics; Rain Therapeutics; Regeneron; Springworks Therapeutics; TYME
Speakers' Bureau - Amgen; Boehringer Ingelheim; Karyopharm Therapeutics
Patents, Royalties, Other Intellectual Property - GODDESS PRO Desmoid Tumor (Inst); UpToDate
Travel, Accommodations, Expenses - Epizyme
Other Relationship - Desmoid Tumor Research Foundation
(OPTIONAL) Uncompensated Relationships - Athenex; Foundation Medicine
 
Ping Chi
Stock and Other Ownership Interests - ORIC Pharmaceuticals (I)
Consulting or Advisory Role - Deciphera; NewBay Pharma; Zai Lab
Research Funding - Deciphera (Inst); NewBay Pharma (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from ORIC (I)
 
Sujana Movva
Consulting or Advisory Role - Genmab
Research Funding - Ascentage Pharma Group (Inst); Hutchison MediPharma (Inst); Trillium Therapeutics (Inst)
 
Ciara Marie Kelly
Employment - Daichii Sankyo (I)
Stock and Other Ownership Interests - daichii sankyo (I)
Consulting or Advisory Role - ChemoCentryx; Exicure; Immunicum; Immunicum; Kartos Therapeutics; SERVIER
Research Funding - AGIOS (Inst); Amgen (Inst); Curadev (Inst); Exicure (Inst); INCYTE (Inst); Kartos Therapeutics (Inst); Merck (Inst); Regeneron (Inst); Servier (Inst); xencor (Inst)
 
Viswatej Avutu
No Relationships to Disclose
 
Jason Earl Chan
Research Funding - Cytek Biosciences (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending for methods to identify and treat high-plasticity cell state driving tumor progression in lung cancer
 
Jae Cho
No Relationships to Disclose
 
Matthew Biniakewitz
No Relationships to Disclose
 
Grace Cho
No Relationships to Disclose
 
Joseph Patrick Erinjeri
Consulting or Advisory Role - AstraZeneca
 
Robert A Lefkowitz
No Relationships to Disclose
 
Cristina R. Antonescu
No Relationships to Disclose
 
Li-Xuan Qin
Employment - Sironax (I)
Leadership - Sironax (I)
Stock and Other Ownership Interests - Sironax (I)
 
Samuel Singer
No Relationships to Disclose
 
William D. Tap
Leadership - Atropos; Certis Oncology Solutions; Innovo Therapeutics
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - Adcendo; Amgen; AmMax Bio; Ayala Pharmaceuticals; Bayer; BioAtla; Boehringer Ingelheim; Cogent Biosciences; Daiichi Sankyo; Deciphera; Epizyme; Foghorn Therapeutics; inhibrx; Kowa Pharmaceutical; Lilly; Medpacto; Servier
Research Funding - AmMax Bio (Inst); Avacta Life Sciences (Inst); BioAtla (Inst); Blueprint Medicines (Inst); C4 Therapeutics (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Theseus Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Enigma and CDH18 as companion Diagnostics for CDK4 inhibition – SKI2016-021-03